Cisplatin, carboplatin, and oxaliplatin are widely used anticancer drugs. Their efficacy is strongly reduced by development of cell resistance. Down-regulation of CTR1 and up-regulation of the Cu-ATPases, ATP7A and ATP7B, have been associated to augmented drug resistance. To gain information on translocation of Pt drugs by human Cu-ATPases, we performed electrical measurements on the COS-1 cell microsomal fraction, enriched with recombinant ATP7A, ATP7B, and selected mutants, and adsorbed on a solid supported membrane. The experimental results indicate that Pt drugs activate Cu-ATPases and undergo ATP-dependent translocation in a fashion similar to that of Cu. We then used NMR spectroscopy and ESI-MS to determine the binding mode of these drugs to the first N-terminal metal-binding domain of ATP7A (Mnk1).

Translocation of Platinum Anticancer Drugs by Human Copper ATPases ATP7A and ATP7B / F. Tadini-Buoninsegni; G. Bartolommei; M.R. Moncelli; G. Inesi; A. Galliani; M. Sinisi; M. Losacco; G. Natile; F. Arnesano. - In: ANGEWANDTE CHEMIE. INTERNATIONAL EDITION. - ISSN 1433-7851. - STAMPA. - 53:(2014), pp. 1297-1301. [10.1002/anie.201307718]

Translocation of Platinum Anticancer Drugs by Human Copper ATPases ATP7A and ATP7B.

TADINI BUONINSEGNI, FRANCESCO;BARTOLOMMEI, GIANLUCA;MONCELLI, MARIA ROSA;
2014

Abstract

Cisplatin, carboplatin, and oxaliplatin are widely used anticancer drugs. Their efficacy is strongly reduced by development of cell resistance. Down-regulation of CTR1 and up-regulation of the Cu-ATPases, ATP7A and ATP7B, have been associated to augmented drug resistance. To gain information on translocation of Pt drugs by human Cu-ATPases, we performed electrical measurements on the COS-1 cell microsomal fraction, enriched with recombinant ATP7A, ATP7B, and selected mutants, and adsorbed on a solid supported membrane. The experimental results indicate that Pt drugs activate Cu-ATPases and undergo ATP-dependent translocation in a fashion similar to that of Cu. We then used NMR spectroscopy and ESI-MS to determine the binding mode of these drugs to the first N-terminal metal-binding domain of ATP7A (Mnk1).
2014
53
1297
1301
F. Tadini-Buoninsegni; G. Bartolommei; M.R. Moncelli; G. Inesi; A. Galliani; M. Sinisi; M. Losacco; G. Natile; F. Arnesano
File in questo prodotto:
File Dimensione Formato  
Angewandte_2014.pdf

Accesso chiuso

Tipologia: Versione finale referata (Postprint, Accepted manuscript)
Licenza: Tutti i diritti riservati
Dimensione 1.33 MB
Formato Adobe PDF
1.33 MB Adobe PDF   Richiedi una copia

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/830508
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 79
  • ???jsp.display-item.citation.isi??? 73
social impact